Integrated Biopharma Inc (INBP)
INBP is quoted over the counter, not listed on an exchange. Integrated Biopharma Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | INBP, quoted over the counter |
| SEC CIK | 0001016504 |
| OTC Markets tier | OTCQX (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Hillside, NJ |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $4.5M cash; operating cash flow $310K a quarter. | Report 2026-06-30 |
| Shares outstanding | 31,059,610 (2026-11-13); 31,059,610 a year earlier; 30,099,610 three years earlier. | Cover page 2026-11-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | $9.8M | -$1.4M | -$1.2M | $4.5M | No debt tags | $43.9M | 10-K 2026-09-25 |
| Q3 2026 2026-03-31 | $10.1M | -$837K | $517K | $5.8M | No debt tags | $48.3M | 10-Q 2026-05-08 |
| Q2 2026 2025-12-31 | $11.3M | -$762K | $617K | $5.3M | No debt tags | $52.1M | 10-Q 2026-02-11 |
| Q1 2026 2025-09-30 | $12.7M | $123K | $1.3M | $4.7M | No debt tags | $53.4M | 10-Q 2025-11-10 |
| Q4 2025 2025-06-30 | $14.2M | -$178K | $591K | $3.6M | No debt tags | $54.4M | 10-K 2026-09-25 |
| Q3 2025 2025-03-31 | $13.9M | $611K | $616K | $3.0M | No debt tags | $52.9M | 10-Q 2026-05-08 |
| Q2 2025 2024-12-31 | $12.6M | $116K | $201K | $2.5M | No debt tags | $52.1M | 10-Q 2026-02-11 |
| Q1 2025 2024-09-30 | $13.6M | $259K | $657K | $2.3M | No debt tags | $51.0M | 10-Q 2025-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2008-05-06 |
| Latest annual report | 10-K | 2026-09-25 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-10-28 |
Source: SEC EDGAR submissions feed, 559 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier